Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Kallikrein 13 Antibodies:
anti-Rat (Rattus) Kallikrein 13 Antibodies:
anti-Mouse (Murine) Kallikrein 13 Antibodies:
Go to our pre-filtered search.
kallikrein (show KLK1 Antibodies) mK13 is a plausible candidate for the processing enzyme for pro-IL-1beta (show IL1B Antibodies) in the submandibular gland of mice
This first clinical study of KLK13 in bladder cancer reveals its deregulated expression in bladder tumors and highlights KLK13 as a promising marker for improving TaT1 patients' prognosis following treatment.
Our results suggest that KLK13 mRNA expression constitutes a novel biomarker for the prediction of overall survival in nonsmall cell lung cancer and that its quantitative assessment in tumor tissues can aid in treatment decision making.
KLK13 may play an important role in regulating cellular migration and invasiveness, making the loss of KLK13 a potential biomarker for early detection of lymph node metastasis in oral squamous cell carcinomas.
The aim of this study was to monitor serum levels of two microRNAs (miR-21 and miR-141) and three kallikreins (hK3/PSA, hK11, and hK13) before and 1, 5, and 30 days after radical prostatectomy.
Data indicate that five out of 9 SNPs in the KLK13 gene were associated with prostate cancer risk and/or aggressiveness.
High KLK13 expression is associated with drug response in gastric cancer.
Results indicate that KLK13 may play a role in the defense of the upper digestive apparatus and in male reproductive organs.
Serine protease (show F2 Antibodies) of Kazal-type (SPINK6 (show SPINK6 Antibodies)) expressed in normal human skin is a potent natural inhibitor of Kallikrein (show KLK4 Antibodies)-related peptidases, KLK12 (show KLK12 Antibodies) and KLK13.
these results reveal the enhancing effects of KLK13 on tumor cell invasion and migration, and that it may serve as a diagnostic/prognostic marker and a potential therapeutic target for lung cancer.
This is the first study disclosing the possible clinical utility of KLK13 as a new tumor biomarker capable of predicting a favorable outcome for gastric cancer patients.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Expression of this gene is regulated by steroid hormones and may be useful as a marker for breast cancer. An additional transcript variant has been identified, but its full length sequence has not been determined.
, kallikrein-like gene 4
, kallikrein-like protein 4